Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Abildgaard

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Blood|April 1, 1994
Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study GroupP M Mannucci, D B Brettler, L M Aledort, et al.
The American Journal of Pediatric Hematology/Oncology|January 1, 1989
Acquired von Willebrand's syndrome with lupus-like serologyN Igarashi, M Miura, E Kato, et al.
Thrombosis and Haemostasis|December 17, 1985
Multicenter comparison of von Willebrand factor multimer sizing techniques. Report of the Factor VIII and von Willebrand Factor SubcommitteeP M Mannucci, C F Abildgaard, H R Gralnick, et al.
The New England Journal of Medicine|December 27, 1990
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study GroupR S Schwartz, C F Abildgaard, L M Aledort, et al.
Thrombosis and Haemostasis|February 1, 1996
Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotypeM A Jarvis, L G Levin, J A Harrison, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Blood|April 1, 1994
Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study GroupP M Mannucci, D B Brettler, L M Aledort, et al.
The American Journal of Pediatric Hematology/Oncology|January 1, 1989
Acquired von Willebrand's syndrome with lupus-like serologyN Igarashi, M Miura, E Kato, et al.
Thrombosis and Haemostasis|December 17, 1985
Multicenter comparison of von Willebrand factor multimer sizing techniques. Report of the Factor VIII and von Willebrand Factor SubcommitteeP M Mannucci, C F Abildgaard, H R Gralnick, et al.
The New England Journal of Medicine|December 27, 1990
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study GroupR S Schwartz, C F Abildgaard, L M Aledort, et al.
Thrombosis and Haemostasis|February 1, 1996
Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotypeM A Jarvis, L G Levin, J A Harrison, et al.
Pageof 5